
REGENXBIO (RGNX) Stock Forecast & Price Target
REGENXBIO (RGNX) Analyst Ratings
Bulls say
Regenxbio is an innovative biotechnology company with a strong pipeline of gene therapy treatments for various genetic defects and diseases. They have a solid financial position with a projected market value of $1.68B and a price objective of $26 per share. The company has strategically aligned with the FDA for the resubmission of the BLA for NAVSUNLI, and their Phase 3 trials for subretinal and suprachoroidal sura-vec are on track, with expected topline results in 4Q26. They have also reported positive topline data for their DMD gene therapy and have a promising outlook for FDA approval.
Bears say
Regenxbio is a clinical-stage biotechnology company with a negative outlook due to several key factors. These include the uncertainty surrounding the success and approval of its gene therapy candidates, potential competition in the market, and potential dilution risks. Additionally, the company's projected financials do not support strong growth potential, as evidenced by its low revenue and net income figures.
This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.
REGENXBIO (RGNX) Analyst Forecast & Price Prediction
Start investing in REGENXBIO (RGNX)
Order type
Buy in
Order amount
Est. shares
0 shares